PTAB: Roche patent can’t evade IPR under Fintiv

11-01-2022

Muireann Bolger

PTAB: Roche patent can’t evade IPR under Fintiv

Sundry Photography / Shutterstock.com

Roche unit Chugai failed to persuade the US Patent Trial and Appeal Board (PTAB) that it should not institute inter partes reviews (IPRs) of a patent covering Actemra (Atlizumab), a treatment for arthritis under the NHK/Fintiv rule.


PTAB, Roche, patent , IPR, Fintiv, Actermra

LSIPR